Israel Teva Pharmaceutical Industry Co., Ltd. and IBM announced on Wednesday that they will promote the development of new drugs on the IBM Watson Health Cloud platform and help patients with chronic diseases achieve disease cloud management.
Machine learning-based IBM Watson Health Cloud Platform is a platform-as-a-service (PaaS) based on user health data designed to help healthcare organizations gain customized insights into patients and a comprehensive understanding of the many factors that affect human health.
The expanded collaboration between the two companies highlights the fact that the two areas of drug discovery and cognitive computing therapy are increasingly intersecting, with the goal of improving and optimizing the patient's target drug, improving drug efficacy and reducing costs.
In a joint statement, IBM and Teva said that they will start a three-year new research collaboration, develop new technologies, and help researchers adjust drug use and discover new uses of existing drugs through a systematic approach.
Of the applications approved by the US Food and Drug Administration (FDA) in recent years, 30% are for new uses of approved drugs and vaccines. Drug discovery and development through re-use methods can solve the problem of time-consuming and costly new treatments. This process can last for 20 years and costs more than $2.5 billion.
Teva and IBM said in a statement that the new research collaboration aims to design, build and implement a system process for drug reuse for drug reuse. The process combines human insight, unique machine algorithms, and a realistic basis for evaluation by the IBM Watson Health Cloud. The statement pointed out that IBM Watson Health Cloud technology will be "large-scale" applications aimed at revealing the unknown relationship between drug molecules and sanitary conditions.
Teva and IBM also said that their chronic disease management program will first target respiratory and central nervous system diseases, which will be the first to combine weather data and analysis from IBM's weather forecasting company The Weather Company. .
The statement said that chronic diseases are a burden for patients in countries around the world and the health care system. Despite the existence of available drugs for decades, many people with asthma or other widely spread chronic diseases are still unable to cure. It is estimated that by 2025, there will be 400 million asthma patients worldwide.
Teva and IBM said that in response to the global impact of chronic diseases, the two companies are currently working together to combine Teva's drugs with IBM Watson's cognitive computing to help patients, healthcare providers and their customers. Better understand and control chronic diseases and follow up treatment.
Sea Shrimp Series,Pink Shrimp,Headless Pink Shrimp,Headless Ramboo Prawn
GOLD STAR FISHERY ZHOUSHAN CO.,LTD. , https://www.goldstar-aquatic.com